BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11394504)

  • 21. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
    Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
    Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.
    Small EJ; Weiss GR; Malik UK; Walther PJ; Johnson D; Wilding G; Kuzel T; Bajamonde A; Paton V
    Cancer J Sci Am; 1998; 4(3):162-7. PubMed ID: 9612597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2.
    Correale P; Marsili S; Sabatino M; Montagnani F; Giorgi G; Francini G
    Oncol Rep; 2005 Apr; 13(4):751-6. PubMed ID: 15756453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma.
    Koulova L; Novik Y; Caliendo G; Wiernik P; Dutcher J
    J Immunother; 2005; 28(6):576-81. PubMed ID: 16224275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.
    Westermann J; Hecker AC; Flörcken A; Dörken B; Pezzutto A
    J Immunother; 2009; 32(6):667-75. PubMed ID: 19483643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
    Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.
    Gleave ME; Elhilali M; Fradet Y; Davis I; Venner P; Saad F; Klotz LH; Moore MJ; Paton V; Bajamonde A
    N Engl J Med; 1998 Apr; 338(18):1265-71. PubMed ID: 9562580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
    Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulocyte-macrophage colony-stimulating factor and interferon-alpha 2B in patients with advanced renal cell carcinoma.
    Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
    Urol Int; 1998; 61(4):215-9. PubMed ID: 10364752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program].
    Tourani JM; Jaillon-Abraham C; Lucas V; Chrétien Y; Mayeur D; Di Palma M; Boaziz C; Grise P; Varette C; Pavlovitch JM; Larregain D; Ecstein E; Untereiner M; Andrieu JM
    Bull Cancer; 1997 Apr; 84(4):351-6. PubMed ID: 9238157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
    Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with subcutaneous interleukin-2 and interferon-alpha in advanced renal cancer patients with poor prognostic factors.
    Canobbio L; Curotto A; Cannata D; Miglietta L; Lavarello A; Giglio C; Franchini R; Cussotto M; Boccardo F
    Anticancer Res; 1996; 16(1):541-4. PubMed ID: 8615668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
    Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
    J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
    Ridolfi L; Ridolfi R
    Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
    Schwaab T; Tretter C; Gibson JJ; Cole BF; Schned AR; Harris R; Wallen EM; Fisher JL; Waugh MG; Truman D; Stempkowski LM; Crosby NA; Heaney J; Ernstoff MS
    J Urol; 2004 Mar; 171(3):1036-42. PubMed ID: 14767265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.